Semaglutide vs. Tirzepatide in 2026: Same Two Molecules, Nine Different Pharmacies

Semaglutide vs. tirzepatide: the same two molecules, nine different pharmacies

SURMOUNT-5 wrapped in 2025 and gave the field a number people could finally argue about instead of guess at. Over 72 weeks, tirzepatide took patients to roughly −20.2% of baseline body weight. Semaglutide, in the same trial, landed at −13.7%. That is the first direct head-to-head of the two molecules that matter most for obesity treatment right now, and it settles the "which one loses more weight, on average" question with fewer asterisks than the usual cross-trial math.

If you are reading this in Chicago, that comparison looks like Wegovy vs. Zepbound. In Seoul, the same two molecules are 위고비 and 마운자로. In Tokyo, ウゴービ has a label but tirzepatide still does not. In Shanghai, both obesity brands (诺和盈 and 穆峰达) are on shelves. Nine markets, two molecules, nine different pricing shelves and coverage stories.

The useful thing is to understand the molecules first, then see how the same pair shows up around the world. US pricing and access get the most airtime below because that is the most common frame, but the international reality is here for anyone traveling, sourcing, or counseling patients across borders.

Two molecules doing two different jobs at the receptor

Semaglutide is a single-receptor agonist. It mimics GLP-1, a gut hormone released after eating, and it binds only the GLP-1 receptor. Slower gastric emptying, quieter appetite signaling in the hypothalamus, better glucose-dependent insulin secretion. That is one lever, pulled hard.

Tirzepatide does two things at once. It is a dual agonist of the GIP receptor and the GLP-1 receptor. GIP is the other big incretin hormone, and on its own GIP is a relatively weak weight-loss lever. But pairing GIP agonism with GLP-1 agonism appears to do more than either pathway alone — better insulin sensitivity, measurably different lipid handling, and what seems to be potentiated satiety signaling. The mechanism is still being worked out in animal and early human models, but the clinical output is not subtle.

That mechanistic gap is why the numbers diverged even before SURMOUNT-5 directly compared them. STEP 1, published in NEJM in 2021, put semaglutide 2.4 mg weekly at −14.9% over 68 weeks in adults with obesity and no diabetes. SURMOUNT-1, published the next year, put tirzepatide 15 mg weekly at −22.5% over 72 weeks in a similar population. Roughly 7 to 8 percentage points, across separate trials, with slightly different durations.

Cross-trial comparisons always carry a caveat. Populations are not identical, endpoints drift, placebo arms vary. That is exactly why SURMOUNT-5 mattered — it put both drugs in the same room.

What SURMOUNT-5 actually showed

Head-to-head, 751 adults with obesity and no diabetes, 72 weeks, maximum tolerated doses of either tirzepatide (10 or 15 mg weekly) or semaglutide 2.4 mg weekly. Result: −20.2% vs −13.7%. Relative difference, roughly 47% more weight lost on tirzepatide.

A patient starting at 200 lb loses about 27 lb on semaglutide and about 40 lb on tirzepatide. Starting at 90 kg, that is about 12 kg vs about 18 kg. For somebody whose clinical target is 10 to 12% off baseline — enough to shift blood pressure, fasting glucose, sleep quality — either drug clears the bar. For someone chasing past 20%, tirzepatide did it in a majority of SURMOUNT-5 participants and semaglutide did it in a minority.

The head-to-head closed the debate on the average, not on the individual. Response is still a distribution, not a single line.

A second number worth holding onto: SELECT, the cardiovascular outcomes trial for semaglutide 2.4 mg, ran about 40 months and reported a 20% reduction in major adverse cardiovascular events in people with established cardiovascular disease and obesity or overweight. That is what earned Wegovy a cardiovascular indication in the US and EU. Tirzepatide does not have a comparable outcomes readout yet — SURPASS-CVOT is ongoing and readers will not see its primary endpoint for a while. So tirzepatide is ahead on average weight loss, and semaglutide is ahead on documented cardiovascular benefit. Both things are true at the same time.

Nine markets, same two molecules, nine different shelves

Brand names shift the second you cross a border. Regulator-level snapshot as of April 2026:

Only the US splits the tirzepatide brand. Zepbound is the obesity label; Mounjaro is the type 2 diabetes label. Everywhere else on this list, tirzepatide is sold under a single brand (Mounjaro, or its localized equivalent) for both conditions. A Korean patient on 마운자로 does not get a second brand for obesity; the same pen covers both approved uses. A US reader traveling internationally should expect to see "Mounjaro" on obesity prescriptions overseas and not be surprised.

Japan has no obesity indication for tirzepatide yet. マンジャロ has been approved for type 2 diabetes since 2022 and launched in April 2023, but the obesity indication has not cleared PMDA as of April 2026. For Japanese patients specifically looking at obesity treatment, ウゴービ is the only labeled GLP-1 option, and it is 自費 (self-pay) territory — roughly 70,000–84,000 JPY per month.

Korea's tirzepatide obesity approval came late 2024 and supply is still catching up. 위고비 launched in October 2024 and had queue problems almost immediately; 마운자로 for obesity was approved in December 2024 with first pharmacy stock arriving through 2025. Cash pricing is 21–37만원 per month for 위고비 depending on dose, and roughly 17–27만원 for 마운자로.

China already has both obesity brands on shelves. 诺和盈 (Novo's obesity brand name for semaglutide in mainland China) launched in November 2024. 穆峰达, Lilly's tirzepatide brand, got the obesity indication and launched in 2025. Both are self-pay through private pharmacies and some urban telehealth clinics.

Ozempic is not Wegovy. This is the single most common mix-up in consumer conversations across every market on this list. The type 2 diabetes semaglutide brand is almost always a different name and a different dose ceiling from the obesity semaglutide brand: Ozempic vs Wegovy in the US, 오젬픽 vs 위고비 in Korea, オゼンピック vs ウゴービ in Japan, 诺和泰 vs 诺和盈 in mainland China. Same molecule, different label, different pen, different cost. Worth being precise about when you are comparing notes with a friend overseas.

Dose ladders: five steps vs six steps

Both drugs titrate. You do not start at the therapeutic dose. That is not a marketing story — it is a tolerance story. GI side effects are dose-dependent, and slow escalation is how you get past the first two months without quitting.

Semaglutide has five rungs; tirzepatide has six. The usual timeline to reach top dose is roughly 16–20 weeks for semaglutide and 20–24 weeks for tirzepatide, assuming no pauses for GI trouble. Most patients do end up pausing or stepping back at least once, so real-world time-to-max often stretches longer.

US readers have one new wrinkle: oral Wegovy at 25 mg daily was approved by the FDA in January 2026 and is starting to appear on formularies. The oral ladder is a single-step titration at 25 mg, and it replaces the pen entirely for patients who can't or won't inject. Tirzepatide has no oral option. Dual agonists are harder to deliver orally — bigger molecule, more complex — and Lilly's oral program is focused on orforglipron (Foundayo), a separate GLP-1 mono-agonist, not an oral tirzepatide.

Side effects: close profiles, not identical

GI symptoms dominate both drugs. They peak during titration, fade across weeks 8 to 12, and are the #1 reason people discontinue.

Tirzepatide looks slightly gentler on GI symptoms at the top dose, and the SURMOUNT-5 head-to-head broadly agreed — nausea was a few percentage points lower on tirzepatide arms. In practice, that difference is smaller than a patient's individual variation. Some people sail through semaglutide and feel wrecked on tirzepatide. Some have the opposite experience. The tolerability profile is a trend, not a destiny.

The rarer serious signals apply to both molecules in roughly the same way:

• Acute pancreatitis — infrequent but real. Sharp, persistent abdominal pain that radiates to the back deserves same-day medical attention, not a wait-and-see.
• Gallbladder disease — rapid weight loss of any kind raises gallstone risk; GLP-1 drugs appear to nudge the baseline risk upward.
• Diabetic retinopathy worsening — documented for semaglutide in patients with type 2 diabetes and pre-existing retinopathy. Worth naming at your visit if you have diabetic eye disease.
• Hypoglycemia — not from GLP-1 drugs alone, but in combination with insulin or a sulfonylurea, the risk climbs fast. Dose adjustments of the other drugs are standard practice.
• Thyroid C-cell tumor warning — both drugs carry a boxed warning based on rodent data. Personal or family history of medullary thyroid carcinoma or MEN2 is a hard contraindication for both.

"Month three was the turning point. The sulfur burps got better, the nausea got quieter, and the scale started moving for real." — a common rhythm people describe on r/GLP1 and r/Zepbound. Trust the arc, not any single week.

Safety context that belongs up front, not in the fine print

A few things worth having on your tongue before the visit, not read off a pamphlet afterward.

Pregnancy. Neither drug is approved in pregnancy. Both Novo Nordisk and Lilly recommend stopping at least two months before a planned conception, given the long half-life of these molecules (roughly a week) and the theoretical risks to fetal development. If you are of reproductive age and not planning pregnancy, reliable contraception is part of the plan — not an afterthought.

Medication interactions. GLP-1 drugs slow gastric emptying, which can affect absorption of oral medications with narrow therapeutic windows. Warfarin, thyroid hormone, some seizure medications — worth mentioning the full list of what you take, including the supplements you would rather not admit to.

The insulin and sulfonylurea interaction is the big one for patients with type 2 diabetes. A GLP-1 drug layered on top of either often requires a dose reduction of the older agent, and the endocrinologist should be the one making that call.

Patients sometimes assume stopping abruptly is fine because there is no physical dependence. No withdrawal in the classical sense, true. But STEP 4 data showed that stopping semaglutide led to about two-thirds of the lost weight coming back within a year. That is not a side effect of stopping — that is obesity behaving like a chronic condition. The decision to stop is legitimate. The expectation that the weight stays off without treatment usually is not.

The compounded question (mostly a US thing now)

From late 2022 through early 2024, shortages of both semaglutide and tirzepatide pushed tens of thousands of US patients toward compounded GLP-1s — drugs made by 503A or 503B pharmacies, not FDA-approved but legal while the branded products were on the FDA shortage list.

By April 2026, both branded products are off the shortage list. Tirzepatide came off in late 2024; semaglutide came off in early 2025. That means compounded versions of either molecule are no longer broadly permitted. The FDA has been sending warning letters and the larger telehealth compounders have largely transitioned to branded cash-pay pricing through LillyDirect and NovoCare.

This matters for non-US readers too, indirectly. Any social-media ad that looks like it is offering compounded tirzepatide at a suspiciously low price in 2026 is almost certainly unlicensed or unsafe, regardless of what country you see it in. The shortage loophole that justified compounded GLP-1s at scale is closed.

US pricing in April 2026, and what the other eight markets look like

US commercial list prices are the largest on the planet and the cash-pay programs have become the more practical reference.

• Wegovy — list around $1,349 per month. NovoCare cash-pay around $499 per month for eligible patients without insurance coverage.
• Oral Wegovy 25 mg — around $499 per month cash.
• Zepbound — list around $1,086 per month. LillyDirect cash-pay around $349 at the 2.5 mg starter dose, stepping up toward $499 at higher doses.

For context against the rest of the list:

• Korea — 위고비 21–37만원/mo; 마운자로 17–27만원/mo. Both 비급여.
• Japan — ウゴービ self-pay about 70,000–84,000 JPY/mo. マンジャロ for T2D only, 7,000–15,000 JPY/mo at 3-wari insurance.
• China — 诺和盈 about 1,300–1,800 元/mo. 穆峰达 about 1,500–2,000 元/mo.
• Taiwan — Wegovy about NT$8,000–12,000/mo. 猛健樂 about NT$7,500–11,000/mo.
• Hong Kong — Wegovy about HK$3,500–5,000/mo. Mounjaro similar.
• Spain — Wegovy private pharmacy about 380–410 €/mes. Public reimbursement limited.
• France — Wegovy private pay about 300–400 €/mo. Mounjaro obésité has conditional reimbursement since late 2024 for select patients.
• Saudi Arabia — Wegovy about 1,200–1,800 SAR/mo. Mounjaro about 1,500 SAR/mo.
• UAE — Wegovy about 1,800–2,400 AED/mo. Mounjaro about 2,000 AED/mo.

All figures are April 2026 snapshots and shift regularly as manufacturer programs change and local supply tightens or loosens.

Private-pay almost everywhere outside the US, even in markets with strong public healthcare. Obesity treatment is still largely out-of-pocket globally, and that is the most honest line to open a family conversation with.

Questions worth bringing to your next visit

Screenshot these. Nine out of ten people walk in with two vague ones and walk out with three new ones.

1. Given my weight, my comorbidities, and my family history, which molecule would you start me on, and why that one?
2. If I tolerate the starter dose well, how fast do you typically escalate?
3. What is my target? A percentage of baseline, a number on the scale, or a clinical marker like HbA1c or blood pressure?
4. If nausea or constipation becomes disruptive in the first six weeks, what is your protocol — hold the dose, step back, add a supportive medication, or ride it out?
5. If my plan denies the prior authorization, what language do you usually use in the appeal?
6. What muscle-loss and protein-intake guidance do you give patients on these drugs?
7. When and how do you think about stopping, and what is your maintenance approach after goal weight?
8. Is there anything in my history — thyroid nodules, gallbladder, pancreatitis, retinopathy, pregnancy plans — that would change the answer to question 1?

Those eight cover most of what goes wrong in the first six months of treatment. Clinicians appreciate specific questions far more than "so what do you think?"

Where your market sits in April 2026

A locale-by-locale read. Skip to the one that matches you.

If you are in the US, you have both molecules on shelves with the cleanest cash-pay programs in the world, a Medicare loophole for Wegovy's cardiovascular indication, and messy commercial-insurance coverage that depends heavily on your employer's formulary. The oral Wegovy 25 mg launch in January 2026 is the newest wrinkle and will matter most for patients who can't do injections.

If you are in Korea, both molecules are available and 비급여. Supply for 위고비 was rough through late 2024 and has steadied; 마운자로 obesity launched in 2025 and some dose strengths are still harder to find in specific pharmacies.

If you are in Japan, tirzepatide for obesity is not yet on the table. ウゴービ is the only labeled option and it is 自費. If tirzepatide obesity approval clears PMDA later in 2026 or 2027, that is the shift to watch.

If you are in mainland China, both obesity brands (诺和盈 and 穆峰达) are available via private pharmacy or urban telehealth. Self-pay. Grey-market channels are best avoided given the enforcement environment.

If you are in Taiwan or Hong Kong, you get the full brand set at private-pay pricing, closer to European levels than US levels.

If you are in the EU, local reimbursement determines whether your out-of-pocket looks like France's partial public coverage or Spain's mostly private pay. Both Wegovy and Mounjaro obesity extensions are fully approved — it is the payer side that varies.

If you are in Saudi Arabia or the UAE, both are available, almost entirely private. Some UAE private insurance plans will cover with prior authorization from an endocrinologist; public coverage for obesity is rare.

The molecules are the same everywhere. The shelf is different in every country. If this sounds like treatment worth starting, a focused 20-minute appointment with someone who has prescribed both — and who knows your local coverage rules — is where the real decision gets made.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app